An increasing share of Ozempic prescriptions in Denmark is being purchased without public subsidy, with patients covering the full cost themselves. According to data from the Danish Health Data Authority (Sundhedsdatastyrelsen), the proportion of Ozempic injection pens sold without state support rose from under 1% at the start of 2024 to around 10% in early 2025.
More Danes self-funding Ozempic treatments
Ulla Kirkegaard Madsen, head of section at the Danish Medicines Agency (Lægemiddelstyrelsen), told the news agency Ritzau that this trend could include type 2 diabetes patients who do not meet the subsidy criteria but still wish to continue treatment. It may also involve patients using Ozempic “off-label” for weight loss.
Some doctors reportedly prescribe Ozempic instead of Wegovy, another semaglutide-based drug, because it can be a cheaper option for patients when paying out of pocket.
Stricter prescription rules drive self-funded Ozempic purchases
Ozempic, developed by Novo Nordisk, contains the same active ingredient as Wegovy. In November 2024, new rules were introduced requiring type 2 diabetes patients to try less expensive alternatives before they can receive Ozempic with public subsidy. This policy change may have contributed to the increase in unsubsidised purchases.
Rising semaglutide demand sparks affordability debate in Denmark
The rising demand for semaglutide-based treatments in Denmark reflects a wider international trend, as these drugs gain popularity for both diabetes management and weight loss. However, the shift towards more self-funded prescriptions could raise questions about accessibility and affordability, particularly for lower-income patients. Danish health authorities are monitoring the situation as the market and prescribing patterns evolve.
